Page Banner

United States Department of Agriculture

Agricultural Research Service

Title: Effect of soy isoflavone supplementation on menopausal quality of life

Authors
item Amato, Paula - OHSU, PORTLAND, OREGON
item Young, Ronald - BAYLOR COLLEGE MED
item Lewis, Richard - UNIV GEORGIA, ATHENS GA
item Murray, Michael - NCFMC, ROSEVILLE CA
item Cramer, Margaret - UNIV GEORGIA, ATHENS GA
item Steinberg, Francene - UNIV CALIFORNIA DAVIS, CA
item Barnes, Stephen - UNIV ALABAMA BIRMINGHAM A
item Ellis, Kenneth
item Fraley, Kennard - BAYLOR COLLEGE MED
item Konzelmann, Karen - BAYLOR COLLEGE MED
item Smith, O'Brian
item Wong, William
item Fischer, Joan - UNIV GEORGIA, ATHENS GA

Submitted to: Journal of Federation of American Societies for Experimental Biology
Publication Type: Abstract Only
Publication Acceptance Date: February 22, 2008
Publication Date: April 7, 2008
Citation: Amato, P., Young, R., Lewis, R., Murray, M., Cramer, M., Steinberg, F., Barnes, S., Ellis, K., Fraley, K., Konzelmann, K., Smith, E.O., Wong, W., Fischer, J. 2008. Effect of soy isoflavone supplementation on menopausal quality of life [abstract]. Journal of Federation of American Societies for Experimental Biology. 22:303.3

Technical Abstract: Recent clinical trials have found an increased risk of health problems in women using menopausal hormone therapy. As a result, women are in search of alternative strategies to improve their quality of life. The purpose of this study was to assess the effect of soy isoflavone supplementation on quality of life in postmenopausal women. Four hundred three healthy postmenopausal women (54.0+/-4.0 yrs) were enrolled in a 2-year multicenter, randomized, controlled trial designed to evaluate the effect of soy isoflavone supplementiation on the prevention of osteoporosis. Quality of life was assessed as a secondary outcome and was measured using the validated Menopause-Specific Quality of Life Questionnaire (MENQOL) administered at baseline and at annual intervals. Participants were randomly assigned to receive soy isoflavones 80 mg/d, soy isoflavones 120 mg/d, or placebo. Data were analyzed using an analysis of variance (ANOVA). Baseline characteristics were similar among the three groups. There was a non-significant decrease i.e. improvement, in the vasomotor domain score at one and two years compared to baseline in all three groups. However, there were no differences among groups. In conclusion, soy isoflavones provide no added benefit over placebo in terms of qualifty of life as measured by the MENQOL.

Last Modified: 9/10/2014
Footer Content Back to Top of Page